Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Horizon Therapeutics specializes in developing and commercializing innovative medicines for rare diseases, with a focus on autoimmune and inflammatory conditions. Its flagship products, including Tepezza and Krystexxa, have positioned the company as a leader in the niche market of rare disease therapeutics, primarily in North America and Europe.
Horizon Therapeutics generates revenue through the sale of specialty pharmaceuticals that target rare diseases, leveraging strong pricing power due to limited competition in these therapeutic areas. The company benefits from a robust pipeline of products and a strategic focus on high-value treatments, which enhances its competitive advantage.
Regulatory approvals for new indications or products
Sales growth of Tepezza and Krystexxa
Pipeline developments and clinical trial results
Market share changes in the rare disease therapeutic space
Regulatory changes affecting drug pricing and reimbursement policies
Potential for technological disruption in drug development
Emergence of generic competitors for existing products
Increased competition from biotech firms in rare diseases
Moderate debt levels could constrain financial flexibility if market conditions worsen
Potential liquidity risks if cash flow generation declines
low - the demand for rare disease treatments is less correlated with economic cycles, as these are often essential medications.
Interest rates have a minimal direct impact on Horizon's operations; however, higher rates could affect overall market valuations and investor sentiment.
minimal - the company has a manageable debt-to-equity ratio of 0.51, indicating low reliance on credit.
growth - investors are drawn to Horizon for its potential in expanding its rare disease portfolio and pipeline.
moderate - the stock has shown stability but can be affected by clinical trial outcomes and regulatory news.